NAACCR Item #3956: p16
| Item # | Length | Source of Standard | Year Implemented | Version Implemented | Year Retired | Version Retired |
|---|---|---|---|---|---|---|
| 3,956 | 1 | SEER | 2022 | 22 |
NAACCR XML: Tumor.p16
The p16 biomarker is over-expressed (produced) in response to HPV. It is therefore a surrogate marker for HPV disease.
Patients with HPV have a different survival or outcome so it is important to be able to distinguish this by documenting the p16 results. Testing is performed by immunohistochemistry (IHC) which is inexpensive and has near universal availability. It has an easily standardized interpretation. HPV testing is usually performed through DNA testing which is more expensive and less widely available. HPV testing also has technically more variability with the interpretation.
p16 is a tumor suppressor protein also known as cyclin-dependent kinase inhibitor 2A. The p16 biomarker is over-expressed (produced) in response to HPV. It is therefore a surrogate marker for HPV disease.
Codes
| 0 | p16 Negative; Nonreactive |
| 1 | p16 Positive; Diffuse, Strong reactivity |
| 8 | Not applicable: Information not collected for this case (If this time is required by your standard setter, use of code 8 will result in an edit error). |
| 9 | Not tested for p16; Unknown |
| Blank | Diagnosis year prior to 2024 |
Note: See the SSDI Manual for coding instructions.
Anus schema added/ Please note for CCCR p16 for Cervix changed from "." to RS* retroactive to 2021